Literature DB >> 9594929

Rationale for and outline of the recommendations of the Working Group on Hypercholesterolemia and Other Dyslipidemias: interim report. Dyslipidemia Working Group of Health Canada.

J Frohlich1, G Fodor, R McPherson, J Genest, N Langner.   

Abstract

A panel consisting of lipidologists, epidemiologists, cardiologists, internists, general practitioners, and public health and government representatives used the evidence-based approach to examine the rationale for a draft of recommendations for medical management of lipid disorders. The proposed recommendations deal with assessment of cardiovascular risk based on history, physical examination and laboratory findings; assessment of the fasting lipid profile; diagnosis and treatment of secondary risk factors; calculation of the 10-year risk of a cardiac event; initiation of lifestyle modifications in patients in whom low density lipoprotein cholesterol (LDL-C), total:high density lipoprotein cholesterol (HDL-C) ratio or triglycerides exceeds target values based on a patient's risk category; follow-up; treatment with drugs; and choices of drugs. In contrast to previous recommendations, there are new, considerably lower, cholesterol level targets for secondary prevention, with a less important emphasis on total cholesterol value than on LDL-C or total:HDL-C ratio and triglyceride levels, and an emphasis on determining the likelihood of a cardiac event by evaluating all relevant risk factors and sharpening the focus on nondrug treatment, which should result in treating a greater percentage of at-risk patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9594929

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  16 in total

1.  Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias.

Authors:  J G Fodor; J J Frohlich; J J Genest; P R McPherson
Journal:  CMAJ       Date:  2000-05-16       Impact factor: 8.262

Review 2.  The postprandial effects of dietary antioxidants in humans.

Authors:  Colin D Kay; Bruce J Holub
Journal:  Curr Atheroscler Rep       Date:  2003-11       Impact factor: 5.113

3.  Family history and the risk of coronary heart disease: comparing predictive models.

Authors:  A Ciampi; J Courteau; T Niyonsenga; M Xhignesse; S Lussier-Cacan; M Roy
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

4.  Statin wars following coronary revascularization - evidence-based clinical practice?

Authors:  Bernard Prigent
Journal:  Can J Cardiol       Date:  2007-03-15       Impact factor: 5.223

5.  Diabetes management: new evidence-based recommendations. Highlights of the 1998 Canadian clinical practice guidelines. Canadian Diabetes Association.

Authors:  S B Harris; A C Macaulay
Journal:  Can Fam Physician       Date:  1998-11       Impact factor: 3.275

6.  The importance of local criteria in the diagnosis of metabolic syndrome in Saudi Arabia.

Authors:  Suhad M Bahijri; Rajaa M Al Raddadi
Journal:  Ther Adv Endocrinol Metab       Date:  2013-04       Impact factor: 3.565

7.  Clinical problem solving based on the 1999 Canadian recommendations for the management of hypertension.

Authors:  R D Feldman; N R Campbell; P Larochelle
Journal:  CMAJ       Date:  1999       Impact factor: 8.262

8.  1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension.

Authors:  R D Feldman; N Campbell; P Larochelle; P Bolli; E D Burgess; S G Carruthers; J S Floras; R B Haynes; G Honos; F H Leenen; L A Leiter; A G Logan; M G Myers; J D Spence; K B Zarnke
Journal:  CMAJ       Date:  1999       Impact factor: 8.262

9.  Lipid screening to prevent coronary artery disease: a quantitative evaluation of evolving guidelines.

Authors:  S A Grover; M Dorais; G Paradis; J G Fodor; J J Frohlich; R McPherson; L Coupal; H Zowall
Journal:  CMAJ       Date:  2000-11-14       Impact factor: 8.262

Review 10.  Fluvastatin: a review of its use in lipid disorders.

Authors:  H D Langtry; A Markham
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.